Microvascular Dysfunction Assessment to Predict Left Ventricular Reverse Remodeling

Patients presenting with idiopathic dilated cardiomyopathy and left ventricle dysfunction (LVEF \<40%), naive of anti-remodeling cardiac medical therapy, will undergo invasive coronary microvascular assessment based on thermodilution. The primary endpoint, namely the left ventricle reverse remodeling, will be assessed after 12 months of optimal medical therapy based on transthoracic echocardiography. The primary endpoint will be evaluated by an independent central core lab. Patients enrolled in the study will be followed for a period of 5 years to monitor their clinical status. During the study period participants may undergo multimodality diagnostic tests including ECG telemetry monitoring, cardiopulmonary exercise testing, cardiovascular cardiac magnetic resonance.

NCT Number	NCT06356727
Lead Sponsor	Azienda Ospedaliera Universitaria Integrata Verona Collaborators: Abbott Medical Devices
Conditions	Heart Failure, Left Ventricular Dysfunction, Idiopathic Dilated Cardiomyopathy
Enrollment	190 participants
Start Date	2024-01-03
Primary Completion	2026-01-31 (estimated)
Study Completion	2030-01-31 (estimated)
Updated on ClinicalTrials.gov	2024-04-10